Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISRCTN59865116Phase 3Completed
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in rectal cancer (2 arms), sponsored by University College London. Primary endpoint: Three-year disease-free survival. Started Nov 2004; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ISRCTN59865116.